Cross sectional study of familial hypercholesterolemia in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis.
10.3760/cma.j.cn112148-20201118-00918
- Author:
Xiao Na WANG
1
;
Fan WANG
1
;
Ping YE
1
;
Da Yi HU
2
;
Shui Ping ZHAO
3
;
Yong Jun WANG
4
;
Yi Ming MU
5
;
Xiao Wei YAN
6
;
Zhan Quan LI
7
;
Yi Dong WEI
8
Author Information
1. Department of Cardiology, Second Medical Center, General Hospital of Chinese People's Liberation Army, Beijing, 100853, China.
2. Department of Cardiology, Peking University people's Hospital, Beijing 100044.
3. Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
4. Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.
5. Department of Endocrinology, First Medical Center, General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
6. Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
7. Department of Cardiology, Liaoning Provincial People's Hospital, Shengyang 110015, China.
8. Department of Cardiology, the Tenth People's Hospital Affiliated to Tongji University, Shanghai 200040, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
China/epidemiology*;
Cholesterol, LDL;
Cross-Sectional Studies;
Dyslipidemias/epidemiology*;
Female;
Humans;
Hyperlipoproteinemia Type II/epidemiology*;
Lipids;
Male;
Middle Aged;
Prevalence;
Risk Factors
- From:
Chinese Journal of Cardiology
2021;49(6):564-571
- CountryChina
- Language:Chinese
-
Abstract:
Objectives: To analyze the incidence, blood lipid levels and cardiovascular disease of familial hypercholesterolemia (FH) in dyslipidemia patients receiving lipid-lowing therapy from the DYSIS-China. Methods: Dyslipidemia International Study-China (DYSIS-China) database was re-analyzed according to the criteria of "Chinese guidelines for prevention and treatment of dyslipidemia in adults-2016 version". DYSIS-China database included 25 317 dyslipidemia out-patients who received at least one lipid-lowering drug for at least three months. All the patients were divided into three groups: unlikely HF, possible FH and definite FH according to the Dutch Lipid Clinic Network diagnostic criteria. Age, gender, lipids levels, drug use and complications were compared among the three groups. Factors were compared between Possible FH group and definite FH group in terms of age stratification. Results: A total of 23 973 patients with dyslipidemia were included. The average age was (64.8±9.9) years, 11 757 patients were females (49.0%). The proportion of unlikely FH in the total population was 20 561 (85.7%), possible FH was 3294 (13.7%), and the definite FH was 118(0.5%). Patients in the definite FH group (58.3±8.5 years) was younger than in unlikely HF(65.3±9.8 years) and possible FH(61.8±9.9 years) group. LDL-C ((5.6±1.9) mmol/L) levels were significantly higher in definite FH group than in unlikely HF ((2.5±0.9) mmol/L) and possible FH ((4.3±1.0) mmol/L) group. TC ((7.4±1.8) mmol/L) levels were also significantly higher in definite FH group than in unlikely HF ((4.3±1.0) mmol/L) and possible FH ((6.0±1.0) mmol/L) group. Percent of female sex, sedentary lifestyle and systolic blood pressure value were significantly higher in definite FH group than in other two groups (all P<0.05). Statin use was similar among the 3 groups. Prevalence of ischemic cardiomyopathy (70(59.3%)) was significantly higher in the definite FH group than in unlikely FH group7519 (36.6%) and possible FH group1149 (34.9%). The rate of hypertension (82 (69.5%)) was also significantly higher in the definite FH group than in unlikely FH group (2 063 (62.6%) and in possible FH group (13 928 (67.7%)). The possible FH group had the highest proportion of patients aged 55-64 years (1 146 (34.8%)), and the prevalence of hypertension 358 (76.8%), diabetes 189 (40.6%), ischemic heart disease 186 (39.9%), cerebrovascular disease 149 (32.0%) and heart failure 28 (6.0%) was the highest in patients over 75 years old. The definite FH group had the highest proportion of patients aged 55-64 years (49 (41.52%)), and the prevalence of ischemic heart disease (70 (59.3%)) was the highest in patients aged 45-54 years old group, there was no significant difference in the prevalence of diabetes,hypertension,heart failure,peripheral artery disease and cerebrovascular disease among different age groups. Conclusion: The detection rate of FH in Chinese patients with dyslipidemia is not low, the blood lipid level is poorly controlled, and the risk of cardiovascular disease is high in Chinses FH patients.
